FDA Is Listening: Adolor Cited For Downplaying REMS At Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
A company representative's oral statement that the REMS for the gastrointestinal surgery recovery drug Entereg is "due to logistics" was unacceptable, DDMAC letter says.
You may also be interested in...
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin
FDA Objects To Claims Based On Low-Quality Evidence In DTC Ads
FDA's Division of Drug Marketing, Advertising and Communications recently used a series of untitled letters to emphasize that the evidence used to make claims in a promotion piece must be of sufficient quality